Work Area: Trade secrets

Latest content

Mysterious patent-purchasing biotech now embroiled in trade secrets dispute

New market entrant Terran Biosciences takes action against rival Compass Pathways in Maryland district court

17 August 2022

IPBC Asia all set for Tokyo this autumn

The Asia-Pacific region’s premier event about the business of IP will take place in the Japanese capital from 31 October to 2 November

10 August 2022

Judicial Yuan announces draft amendments to the Intellectual Property Case Adjudication Act

New amendments encompass 40 new articles, alongside revisions to 41 others. They aim to enhance protection of trade secrets and strengthen communications between the IP Court and the IP Office, among other goals.

03 August 2022

UK government blocks IP deal with Chinese company using radical new powers

Recently implemented legislation gives the British government the ability to intervene in IP transactions

22 July 2022

Taiwan reinforces protections of core technologies and trade secrets

In a bid to prevent core technologies from being leaked to foreign competitors, Taiwan’s Legislative Yuan has amended the National Security Act. However, the amendment raises questions about whether the development of domestic industries will be negatively affected.

20 July 2022

The top takeaways from IPBC Global 2022

After a month of reflection following the successful event in Chicago, which was attended by 600 delegates, IAM reporters pick out the biggest stories that emerged from the three days

13 July 2022

Covid-19 has exposed the limits of compulsory licensing

The pandemic has brought the difficulties of bypassing life sciences IP into plain view

02 July 2022

New IP finance play, Ukraine tribute, patent litigation trends and plenty more as IPBC Global 2022 comes to an end

Despite the close attentions of a tornado and the deadening heatwave that preceded and followed it, delegates and speakers in Chicago were in good form for the final day of this year's event

15 June 2022

Five IP strategy lessons from the Herceptin patent wars

Dispute's over Genentech's trastuzumab have helped write the patent playbook for innovators and imitators in the biologics space

07 June 2022

China’s market watchdog releases 2022 Legislative Plan

The legislative projects covered in the Plan are categorised either as Category I or Category II. It is essential that Category I projects are submitted for compliance checks and internal scrutiny by the deadline to prevent them being demoted to Category II.

01 June 2022

Unlock unlimited access to all IAM content